Interestingly, lower pre-treatment tumor protein expression levels of CHK1 (verified by immunohistochemistry) were associated with response to the panobinostat and erlotinib combination in six patients with NSCLC. This evidence concerns the gene CHEK1 and non-small cell lung carcinoma.